Anaphylactic reaction to a previous dose of influenza vaccine or to any of its components
Known Immunoglobulin E (IgE)-mediated hypersensitivity to eggs manifested as hives, swelling of the mouth and throat, difficulty in breathing, hypotension, or shock
Guillain- Barré syndrome within eight weeks of a previous influenza vaccine
Use of aspirin or salicylate- containing products within 30 days before enrollment
Household members of children in Group A

NCT02871206_exc_T1
Condition
Anaphylactic reaction
NCT02871206_exc_T2
Temporal
previous
NCT02871206_exc_T3
Drug
influenza vaccine
NCT02871206_exc_T4
Drug
its components
NCT02871206_exc_T5
Scope
influenza vaccine or to any of its components
NCT02871206_exc_T6
Condition
Immunoglobulin E (IgE)-mediated hypersensitivity
NCT02871206_exc_T7
Drug
eggs
NCT02871206_exc_T8
Condition
hives
NCT02871206_exc_T9
Condition
swelling of the mouth
NCT02871206_exc_T10
Condition
welling of the hroat,
NCT02871206_exc_T11
Condition
difficulty in breathing
NCT02871206_exc_T12
Condition
hypotension
NCT02871206_exc_T13
Condition
shock
NCT02871206_exc_T14
Scope
hives, swelling of the mouth and throat, difficulty in breathing, hypotension, or shock
NCT02871206_exc_T15
Condition
Guillain- Barré syndrome
NCT02871206_exc_T16
Temporal
within eight weeks of a previous influenza vaccine
NCT02871206_exc_T17
Reference_point
a previous influenza vaccine
NCT02871206_exc_T18
Temporal
previous
NCT02871206_exc_T19
Drug
influenza vaccine
NCT02871206_exc_T20
Drug
aspirin
NCT02871206_exc_T21
Drug
salicylate- containing products
NCT02871206_exc_T22
Temporal
within 30 days before enrollment
NCT02871206_exc_T23
Scope
aspirin or salicylate- containing products
NCT02871206_exc_T24
Person
Household members
NCT02871206_exc_T25
Person
children
NCT02871206_exc_T26
Person
Group A
NCT02871206_exc_T27
Scope
children in Group A